Janssen Biotech

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Bioventus, ESS, IBM, and FATE and Encourages Investors to Contact the Firm

Retrieved on: 
Thursday, February 9, 2023
Maker, IBM, Sale, Person, News, Rule, Cancer, Class, Register, IPO, P.C, Johnson & Johnson, Form, Destiny, FATE, Partnership, Registration statement, Janssen Pharmaceuticals, Knowledge, B-cell lymphoma, ESS, NYSE, Janssen Biotech, Risk, ESI, Prospectus, Acute myeloid leukemia, Shareholder, Form 10-Q, Security (finance), Risk management, Health insurance, Renewable energy, Insurance, Audit, Vaccine, Pharmaceutical industry, Defendant, Plaintiff

Additionally, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and compliance policies.

Key Points: 
  • Additionally, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and compliance policies.
  • As of the time this Complaint was filed, Bioventus's Class A common stock continues to trade below the $13.00 per share Offering price, damaging investors.
  • On this news, Fate’s stock price fell $6.76 per share, or 61.45%, to close at $4.24 per share on January 6, 2023.
  • For more information on the FATE class action go to: https://bespc.com/cases/FATE

Larimar Therapeutics Appoints Dr. Gopi Shankar as Chief Development Officer

Retrieved on: 
Tuesday, February 7, 2023
Drexel University, Disease, MBA, Master of Science, Friedreich's ataxia, Employment, Research, University, Food, MAA, Food and Drug Administration, Janssen Biotech, Fellow, IND, Gopi Shankar Madurai, Janssen Pharmaceuticals, CDO, Larimar, Financial compensation, European Medicines Agency, Clinical pharmaceutical scientist, Immunogenicity, Oklahoma State University–Stillwater, Option, Head, FA, BLA, Patient, Janssen, AAPS, Growth, Philip, Johnson & Johnson, Doctor of Philosophy, Therapy, Pharmaceutical industry, Science, MD

BALA CYNWYD, Pa., Feb. 07, 2023 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced the appointment of Gopi Shankar, PhD, MBA, FAAPS, to the newly created position of Chief Development Officer (CDO).

Key Points: 
  • BALA CYNWYD, Pa., Feb. 07, 2023 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced the appointment of Gopi Shankar, PhD, MBA, FAAPS, to the newly created position of Chief Development Officer (CDO).
  • Dr. Shankar will report directly to Chief Executive Officer Carole Ben-Maimon, MD, and will be responsible for the strategic development of the Company’s clinical and R&D programs, including additional applications of the Company’s platform technology.
  • “We are thrilled to welcome Dr. Shankar to Larimar and look forward to benefiting from his extensive expertise in biologics development, immunology, PK/PD, and bioanalysis,” said Dr. Ben-Maimon.
  • He also previously worked as Senior Director and Head, Bioanalytical Sciences and Immunogenicity at Janssen Research & Development.

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Fate Therapeutics, Inc. (FATE) Investors with Significant Losses to Contact Firm’s Attorneys, Securities Class Action Filed

Retrieved on: 
Monday, February 6, 2023
Person, Complaint, Cancer, Destiny, FATE, News, CAR, Janssen, SAN, Workforce, Janssen Biotech, Steve Berman (lawyer), Therapy, Pharmaceutical industry

SAN FRANCISCO, Feb. 06, 2023 (GLOBE NEWSWIRE) -- Hagens Berman urges Fate Therapeutics, Inc. (NASDAQ: FATE) investors who suffered significant losses to submit your losses now .

Key Points: 
  • SAN FRANCISCO, Feb. 06, 2023 (GLOBE NEWSWIRE) -- Hagens Berman urges Fate Therapeutics, Inc. (NASDAQ: FATE) investors who suffered significant losses to submit your losses now .
  • Under this agreement, Fate received a $50 million up front payment and was eligible to receive up to $3 billion in various milestone payments and royalties.
  • “We’re focused on investors’ losses and proving Fate misled investors about the strength of- and prospects for- its work with Janssen,” said Reed Kathrein, the Hagens Berman partner leading the investigation.
  • If you invested in Fate Therapeutics and have significant losses, or have knowledge that may assist the firm’s investigation, click here to discuss your legal rights with Hagens Berman .

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Bioventus, ESS, IBM, and FATE and Encourages Investors to Contact the Firm

Retrieved on: 
Saturday, February 4, 2023
Maker, IBM, Sale, Person, News, Rule, Cancer, Class, Register, IPO, P.C, Johnson & Johnson, Form, Destiny, FATE, Partnership, Registration statement, Janssen Pharmaceuticals, Knowledge, B-cell lymphoma, ESS, NYSE, Janssen Biotech, Risk, ESI, Prospectus, Acute myeloid leukemia, Shareholder, Form 10-Q, Security (finance), Risk management, Health insurance, Renewable energy, Insurance, Audit, Vaccine, Pharmaceutical industry, Defendant, Plaintiff

Additionally, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and compliance policies.

Key Points: 
  • Additionally, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and compliance policies.
  • As of the time this Complaint was filed, Bioventus's Class A common stock continues to trade below the $13.00 per share Offering price, damaging investors.
  • On this news, Fate’s stock price fell $6.76 per share, or 61.45%, to close at $4.24 per share on January 6, 2023.
  • For more information on the FATE class action go to: https://bespc.com/cases/FATE

FATE INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Fate Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

Retrieved on: 
Wednesday, February 1, 2023
Robbins Geller Rudman & Dowd LLP, Cancer, Janssen Biotech, Destiny, CASE, Janssen, SAN, Therapy, News, Pharmaceutical industry, Tobacco

), the Fate Therapeutics class action lawsuit charges Fate Therapeutics as well as certain of its top executives with violations of the Securities Exchange Act of 1934.

Key Points: 
  • ), the Fate Therapeutics class action lawsuit charges Fate Therapeutics as well as certain of its top executives with violations of the Securities Exchange Act of 1934.
  • A lead plaintiff acts on behalf of all other class members in directing the Fate Therapeutics class action lawsuit.
  • The lead plaintiff can select a law firm of its choice to litigate the Fate Therapeutics class action lawsuit.
  • An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff of the Fate Therapeutics class action lawsuit.

FATE CLASS ACTION: Hagens Berman, National Trial Attorneys, Encourages Fate Therapeutics, Inc. (FATE) Investors with Significant Losses to Contact Firm’s Attorneys, Securities Fraud Class Action Filed

Retrieved on: 
Monday, January 30, 2023
Person, Complaint, Cancer, Destiny, FATE, CAR, Janssen, Workforce, Janssen Biotech, Steve Berman (lawyer), Therapy, News, Pharmaceutical industry

Under this agreement, Fate received a $50 million up front payment and was eligible to receive up to $3 billion in various milestone payments and royalties.

Key Points: 
  • Under this agreement, Fate received a $50 million up front payment and was eligible to receive up to $3 billion in various milestone payments and royalties.
  • The truth emerged on Jan. 5, 2023, when Fate announced that it terminated the Janssen collaboration agreement after Fate declined Janssen’s proposal to continue the agreement on revised terms.
  • “We’re focused on investors’ losses and proving Fate misled investors about the strength of- and prospects for- its work with Janssen,” said Reed Kathrein, the Hagens Berman partner leading the investigation.
  • If you invested in Fate Therapeutics and have significant losses, or have knowledge that may assist the firm’s investigation, click here to discuss your legal rights with Hagens Berman .

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against FATE, and Sotera and Encourages Investors to Contact the Firm

Retrieved on: 
Monday, January 30, 2023
Goldman Sachs, Ethylene oxide, Offerings, Atmosphere, Probability, Culture, News, GTCR, Health, JPMorgan Chase, Cancer, SPO, Class, IPO, Agency, NATA, P.C, Human services, U.S. Department of Commerce Office of Security, Johnson & Johnson, Destiny, FATE, EPA, SHC, Warburg Pincus, Janssen Pharmaceuticals, B-cell lymphoma, Knowledge, Pressure, Therapy, Safety, Human, School, Poison, Janssen Biotech, Risk, Sterilization, Acute myeloid leukemia, Holding company, Vaccine, Pharmaceutical industry, Environmental remediation, Dietary supplement, Tobacco, Renewable energy, Nordion, Sotera Tschetter

Throughout the Class Period, Defendants made materially false and misleading statements regarding the Company’s business, operations, and compliance policies.

Key Points: 
  • Throughout the Class Period, Defendants made materially false and misleading statements regarding the Company’s business, operations, and compliance policies.
  • On January 5, 2023, after the markets closed, Fate issued a press release announcing that it had terminated the Janssen Collaboration Agreement.
  • Sotera, through its Sterigenics business, conducts or has conducted EtO processing at facilities located in Illinois, California, Georgia, and New Mexico.
  • As a result of these misrepresentations, shares of Sotera stock traded at artificially inflated prices throughout the Class Period.

Fate Therapeutics, Inc.: Please contact the Portnoy Law Firm to recover your losses; March 22, 2023 deadline.

Retrieved on: 
Wednesday, January 25, 2023
Destiny, Janssen Biotech, Life insurance, Pharmaceutical industry

​LOS ANGELES, Jan. 24, 2023 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Fate Therapeutics, Inc (“Fate” or “the Company”) (NASDAQ: FATE) investors that a lawsuit filed on behalf of investors that purchased Fate securities (NASDAQ: FATE) between April 2, 2020 through January 5, 2023 (the “Class Period”).

Key Points: 
  • LOS ANGELES, Jan. 24, 2023 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Fate Therapeutics, Inc (“Fate” or “the Company”) (NASDAQ: FATE) investors that a lawsuit filed on behalf of investors that purchased Fate securities (NASDAQ: FATE) between April 2, 2020 through January 5, 2023 (the “Class Period”).
  • Investors are encouraged to contact attorney Lesley F. Portnoy , by phone 844-767-8529 or email : [email protected], to discuss their legal rights, or click here to join the case via www.portnoylaw.com .
  • The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors’ options for pursuing claims to recover their losses.
  • The Portnoy Law Firm represents investors in pursuing claims against caused by corporate wrongdoing.

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Fate Therapeutics, Inc. (FATE) Investors with Significant Losses to Contact Firm’s Attorneys, Securities Fraud Class Action Filed

Retrieved on: 
Monday, January 23, 2023
Person, Complaint, Cancer, Destiny, FATE, News, CAR, Janssen, SAN, Workforce, Janssen Biotech, Steve Berman (lawyer), Therapy, Pharmaceutical industry

SAN FRANCISCO, Jan. 23, 2023 (GLOBE NEWSWIRE) -- Hagens Berman urges Fate Therapeutics, Inc. (NASDAQ: FATE) investors who suffered significant losses to submit your losses now .

Key Points: 
  • SAN FRANCISCO, Jan. 23, 2023 (GLOBE NEWSWIRE) -- Hagens Berman urges Fate Therapeutics, Inc. (NASDAQ: FATE) investors who suffered significant losses to submit your losses now .
  • Under this agreement, Fate received a $50 million up front payment and was eligible to receive up to $3 billion in various milestone payments and royalties.
  • “We’re focused on investors’ losses and proving Fate misled investors about the strength of- and prospects for- its work with Janssen,” said Reed Kathrein, the Hagens Berman partner leading the investigation.
  • If you invested in Fate Therapeutics and have significant losses, or have knowledge that may assist the firm’s investigation, click here to discuss your legal rights with Hagens Berman .

Bragar Eagel & Squire, P.C. Is Investigating Phathom, Super Micro, and Fate and Encourages Investors to Contact the Firm

Retrieved on: 
Thursday, January 19, 2023
Providence Business News, News, Janssen, Destiny, Supermicro, FDA, Janssen Biotech, P.C, Pharmaceutical industry, Audit

NEW YORK, Jan. 18, 2023 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT), Super Micro, Inc. (NASDAQ: SMCI), and Fate Therapeutics, Inc. (NASDAQ: FATE).

Key Points: 
  • NEW YORK, Jan. 18, 2023 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT), Super Micro, Inc. (NASDAQ: SMCI), and Fate Therapeutics, Inc. (NASDAQ: FATE).
  • Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices.
  • Additional information about each case can be found at the link provided.
  • The Company further disclosed that it would prioritize its clinical programs and reduce its operating expenses, through layoffs and the discontinuation of some clinical programs.